ERBB2 and neoplasm: Compared to trastuzumab, it has been shown that these trifunctional antibodies mediate the elimination of tumor cells expressing HER2/neu at low levels, which was associated with a Th1-based cytokine release (82) and a potent antitumor activity (83).